We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HEN:XETRHenkel AG & Co. KGaA Analysis

Data as of 2026-03-11 - not real-time

$171.02

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Jack Henry & Associates (HEN) is trading at $171.02, comfortably above its 20‑day SMA of 163.15 but slightly below the 50‑day SMA of 175.04, indicating a short‑term pullback within a longer‑term uptrend (price > 200‑day SMA of 169.96). The RSI sits at 54.9, suggesting neutral momentum, while the MACD histogram is positive (+2.08) and the MACD line crosses above its signal, flagging a bullish signal. Support sits at 154.18 and resistance at 172.98, placing the current price near the top of its range with limited upside on the near‑term chart. Fundamental metrics show a PE of 24.5, well below the industry average of 36.85, and a dividend yield of 1.37% with a modest payout ratio of 33%, supporting dividend sustainability. However, the DCF‑derived fair value of $89.64 is far beneath the market price, highlighting a potential overvaluation gap, while the 30‑day volatility of 37.6% and decreasing volume suggest heightened short‑term price swings. Recent earnings beat, 7.9% revenue growth, and expanding operating margins reinforce a growth narrative, aligning with analyst consensus of a “buy” rating and a target median price of $205.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance at $172.98
  • Bullish MACD histogram but decreasing volume
  • Neutral RSI indicating no strong momentum

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 7.9% and expanding operating margins
  • PE well below industry average suggesting relative value
  • Target median price of $205 implying ~19% upside

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Secular demand for core banking and payment solutions
  • Sustainable dividend with 33% payout ratio
  • High price‑to‑book ratio and DCF gap indicating valuation caution

Key Metrics & Analysis

Financial Health

Revenue Growth7.90%
Profit Margin20.59%
P/E Ratio24.5
ROE24.28%
ROA13.35%
Debt/Equity3.11
P/B Ratio5.6
Op. Cash Flow$708.2M
Free Cash Flow$335.3M
Industry P/E36.8

Technical Analysis

TrendNeutral
RSI54.9
Support$154.18
Resistance$172.98
MA 20$163.15
MA 50$175.04
MA 200$169.96
MACDBullish
VolumeDecreasing
Fear & Greed Index76.75

Valuation

Fair Value$89.64
Target Price$203.21
Upside/Downside18.82%
GradeFair
TypeGrowth
Dividend Yield1.37%

Risk Assessment

Beta0.40
Volatility37.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.